The identification of novel target molecules for a range of inflammato
ry diseases remains a significant objective for the pharmaceutical ind
ustry. The ultimate goal of this research is the development of new im
munomodulatory compounds that may augment or even replace existing tre
atments. The authors describe the key developments made towards this b
road objective for several therapeutic areas in the light of a recent
conference covering this topic.